Form 4: Intensity Therapeutics CEO Granted Stock Options
SEC Form 4 Filing
Lewis H. Bender, CEO of Intensity Therapeutics, Inc., was granted stock options to purchase 700,000 shares of common stock.
Summary
- Lewis H. Bender, the President and CEO of Intensity Therapeutics, Inc., was granted stock options on May 2, 2025.
- The options allow him to purchase 700,000 shares of common stock at an exercise price of $0.57 per share.
- The options vest in four equal annual installments starting on May 2, 2025, contingent upon continued employment with the company.
- A power of attorney was executed on October 29, 2024, granting certain individuals the authority to file SEC forms on Bender's behalf.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively. The vesting schedule suggests a long-term commitment from the CEO.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes the CEO to remain with the company.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Comparable companies often use similar vesting schedules (e.g., four-year vesting with a one-year cliff) to incentivize long-term performance.
- The size of the grant (700,000 shares) should be evaluated in the context of the company's overall capitalization and the CEO's total compensation package relative to peers.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to drive long-term value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2024-10-29 | Date of execution of Power of Attorney. |
| 2025-05-02 | Date of the earliest transaction (grant of stock options) and the start of the vesting period. |
| 2025-05-06 | Date of signature on the Form 4 filing. |
| 2035-05-02 | Expiration date of the stock options. |
Keywords
stock options, Intensity Therapeutics, Form 4, CEO, Lewis H. Bender, beneficial ownership, securities, power of attorney, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.